Attached files
file | filename |
---|---|
EX-32.1 - EX-32.1 - Revolution Medicines, Inc. | rvmd-ex321_10.htm |
EX-31.2 - EX-31.2 - Revolution Medicines, Inc. | rvmd-ex312_7.htm |
EX-31.1 - EX-31.1 - Revolution Medicines, Inc. | rvmd-ex311_9.htm |
10-Q - 10-Q - Revolution Medicines, Inc. | rvmd-10q_20200630.htm |
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Revolution Medicines, Inc. (the “Company”) on Form 10-Q for the period ending June 30, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
|
(1) |
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|
(2) |
The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. |
Date: August 10, 2020 |
By: |
/s/ Jack Anders |
|
|
Jack Anders |
|
|
Vice President, Finance and Principal Accounting Officer (Principal Financial and Accounting Officer) |